2022
DOI: 10.1136/heartjnl-2022-321179
|View full text |Cite
|
Sign up to set email alerts
|

Correspondence on 'Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation does need confirmation' by Cohenet al

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 8 publications
0
1
0
Order By: Relevance
“…The Authors' reply: We thank Drs Armoiry and Connock for their thoughtful comments and questions1 regarding our report on the cost-effectiveness of transcatheter edge-to-edge mitral valve repair (TEER) for patients with heart failure and severe secondary mitral regurgitation (MR) from the perspective of the UK National Health Service 2. They raise two important questions regarding our analysis: the first regarding alternative approaches to life expectancy projection and the second regarding the disparity between the results of the percutaneous repair with the MitraClip device for severe functional/secondary mitral regurgitation (MITRA-FR) and cardiovascular outcomes assessment of the MitraClip percutaneous therapy for heart failure patients with functional mitral regurgitation (COAPT) trials.…”
mentioning
confidence: 99%
“…The Authors' reply: We thank Drs Armoiry and Connock for their thoughtful comments and questions1 regarding our report on the cost-effectiveness of transcatheter edge-to-edge mitral valve repair (TEER) for patients with heart failure and severe secondary mitral regurgitation (MR) from the perspective of the UK National Health Service 2. They raise two important questions regarding our analysis: the first regarding alternative approaches to life expectancy projection and the second regarding the disparity between the results of the percutaneous repair with the MitraClip device for severe functional/secondary mitral regurgitation (MITRA-FR) and cardiovascular outcomes assessment of the MitraClip percutaneous therapy for heart failure patients with functional mitral regurgitation (COAPT) trials.…”
mentioning
confidence: 99%